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Although it has been established that nifedipine is associated with gingival overgrowth (GO), there is little information on the
prevalence and severity of this condition in the Brazilian population. The aim of this study was to assess the occurrence of
nifedipine-induced GO in Brazilian patients and the risk factors associated using a Clinical Index for Drug Induced Gingival
Overgrowth (Clinical Index DIGO). The study was carried out on 35 patients under treatment with nifedipine (test group) and
35 patients without treatment (control group). Variables such as demographic (age, gender), pharmacological (dose, time of use),
periodontal (plaque index, gingival index, probing depth, clinical insertion level, and bleeding on probing), and GO were assessed.
Statistical analysis showed no association between GO and demographic or pharmacological variables. However, there was an
association between GO and periodontal variables, except for plaque index. According to our study, the Clinical Index DIGO can
be used as a parameter to evaluate GO. Therefore, we conclude that the presence of gingival inﬂammation was the main risk factor
for the occurrence of nifedipine-induced GO.
1.Introduction
Drug-induced gingival overgrowth (DIGO) is a histomor-
phological alteration due to the side eﬀects of a medication
on the extracellular matrix [1]. Several drugs induce gingival
overgrowth, but phenytoin, cyclosporine, and nifedipine
produce signiﬁcant alterations in terms of prevalence and
severity of gingival overgrowth [2].
Nifedipine is a speciﬁc calcium antagonist which inhibits
calcium inﬂux directly from the cells of cardiac muscle
and has a vasodilatory action that causes reduced arterial
pressure [3]. Among calcium antagonists, it is the drug most
commonly related to DIGO [4], whose prevalence ranges
from 20% to 83% [5, 6].
According to Seymour et al. [7], the hypothesis for the
etiology of DIGO is multifactorial. Analysis of variables such
as demographic (patient’s age and gender), pharmacological
(dose, time of use, serum, and salivary concentration of
the drug) and periodontal (plaque index and gingival
inﬂammation), in addition to genetic factors and association
of medications, have been identiﬁed as risk factors for this
condition [7, 8].
The correlation between demographic and pharmaco-
logical variables to the extent and severity of GO has been
studied, aiming at the identiﬁcation of risk situations for
the patients under nifedipine treatment [8–10]. Concerning
the periodontal variables, some studies have suggested a
consensus about the fact that bacterial plaque and gingi-
val inﬂammation are risk factors strongly associated with
nifedipine-induced GO [5, 7, 11].
Most of the indexes used and reported in the literature
for the assessment of DIGO are complicated to use, many
of them require the preparation of plaster casts and many
measurements and procedures that impair their routine use
[5, 7, 11].
Considering the lack of studies on the prevalence and
severity of DIGO related to the use of nifedipine in the
Brazilian population, this study was proposed. Thus, the
objective was to assess nifedipine DIGO in a Brazilian group
of patients and evaluate the possible association with demo-
graphic, pharmacological, and periodontal variables using
the Clinical Index for Drug-Induced Gingival Overgrowth
(DIGO) proposed by Ingl´ es et al. [11].2 ISRN Dentistry
2.MaterialandMethods
2.1. Patient Selection. The protocol for patient care was
approved by the Research Ethics Committee of the Dental
School of Araraquara, UNESP, S˜ ao Paulo, Brazil. Two groups
of patients, test and control, were used. The test group
was selected at the Health Stations of the Municipality
of Araraquara, S˜ ao Paulo, Brazil, among patients with
cardiovascular disease who were under periodical medical
control and who had been taking nifedipine for at least 6
months under medical monitorization. The control group
was selected among patients who sought the Dental School
of Araraquara for dental treatment.
Thefollowinginclusioncriteriawereusedforthetestand
control groups: no periodontal treatment for the preceding 6
months, no use of orthodontic braces or dentures, absence
of defective restorations, and the presence of at least 6
to 12 teeth from the anterior region. Exclusion criteria
were diabetes mellitus, blood dyscrasia, hormonal changes,
pregnancy, oral breathing, smoking, patients taking systemic
antibiotics, or anti-inﬂammatory drugs (steroidal and non-
steroidal), and patients taking contraceptive medication or
any other drug inducing gingival overgrowth.
2.2. Clinical Examination. During clinical examination, a
single examiner(MRS)performedtheanamnesis andachart
was ﬁlled out with the identiﬁcation for Group Test or
Control,patientage,gender,andpharmacologicaldata(dose
and time of use of nifedipine). The gingival areas involved in
the study were photo-documented.
2.3. Periodontal Examination. Gingival Overgrowth (GO)
was assessed in the upper teeth by the method of Ingl´ es et
al. [11]. This method consists of clinical evaluation of the
vestibular and lingual papillae, which were scored from 0
to 4 according to the Clinical Index DIGO [11]. A single
examiner (CPS) blind for identiﬁcation of patients, trained
and calibrated for the Kappa agreement test, performed the
periodontal examination, which consisted of the measure-
ment of the following variables: plaque index (PI) [12],
gingival index (GI) [13], probing depth (PD), bleeding on
probing (PB), and clinical insertion level (CIL).
2.4. Criteria for the Analysis of Periodontal Variables and
Gingival Overgrowth. The data collected during the peri-
odontal examination were divided into groups for statistical
analysis. The variables PI and GI were divided into groups
according to the absence or presence of visible plaque and
according to marginal probing bleeding, respectively, with
scores of 0 (presence) and 1 (absence). PB variable was
divided into groups according to the absence or presence of
bleeding on probing, with scores varying from 0 (presence)
to 1 (absence). The PD and CIL variables were divided into
groups according to intervals of sites with PD and CIL <
3mm, from 3 to 4mm, and ≥5mm. Finally, GO was divided
into groups according to absence (score < 2) and presence
(score ≥ 2).
2.5. Statistical Analysis. The values obtained for the test and
control groups concerning the periodontal variables (PI, GI,
Table 1: Distribution of the demographic and pharmacological
variables in the test and control groups.
Test group Control group
Number of patients 35 35
Age (range) 69.5 ± 2.12 (40–80) 40.5 ± 14.85 (30–73)
Gender
distribution (m:f) 22:13 6:29
Nifedipine dose
(mg/day) 40 ± 11.21 —
Time of nifedipine
use (months) 156 ± 118.79 —
PD, PB, and CIL) and GO were submitted to the Z test at
the 5% level of signiﬁcance (P<. 05) for the comparison
of proportions of relative frequencies [14]. The Spearman
correlation test using the BioEstat 2.0 software [15]w a s
used to calculate the correlations between GO and the
demographic, pharmacological, and periodontal variables.
3. Results
The patient’s data are presented in Table 1, which shows a
higher prevalence of males in the test group, with a mean
age of 69.5 years and a mean daily dose of 40mg for a mean
period of 13 years (156 months) of nifedipine use.
With the use of the Clinical Index DIGO [11], GO was
observed in 68% of the patients in the test group and in 23%
of the patients in the control group. Application of the Z test
demonstrated a signiﬁcant diﬀerence in GO between groups
at the 5% level of signiﬁcance (P<. 05). The values of the Z
test for the comparison of the proportions of GO and of the
periodontal variables between groups are listed in Table 2.
The Z test showed a no signiﬁcant diﬀerence for PI, GI, PD,
and PB between the test and control groups. However, for
CIL the Z test showed a statistically signiﬁcant diﬀerence for
the intervals with CIL < 3mm and CIL from 3 to 4mm.
In Figures 1 and 2 we can observe a higher frequency
for the scores 2 and 3 for PI in the test group and for GI
in the control group. Figures 3 and 4 illustrate the mean
percentages of PD and CIL, demonstrating higher PD and
CIL frequencies in the interval of 3 to 4mm for both groups
and in the PD ≥ 5mm and CIL ≥ 5mm interval for the test
group.
The demographic variables (age and gender) and the
pharmacological variables (dose and time of use of nifedip-
ine) did not show correlation with GO (Table 3). A correla-
tion between degree of severity of GO and CIL < 3mmand
CIL ≥ 5mm was detected only for the test group (Table 4).
The periodontal variable PI was correlated with the degree of
severityofGOonlyinthecontrolgroup.Therewasapositive
correlation between GI, PD, and PB and the degree of GO
severity for both groups.
4. Discussion
Since the ﬁrst report of drug-related GO by Kimbal [16]i n
1939, several studies have been conducted in an attempt toISRN Dentistry 3
Table 2: Z test values for the comparison of the proportions for
periodontal variables between groups.
Variables Scores and intervals Z values
Test × Control
GO <2 −2.32∗
≥22 . 3 2 ∗
PI 0-1 −1.22
2-3 1.24
GI 0-1 0.67
2-3 −0.79
PD
<3mm −1.21
from 3 to 4mm 0.57
≥5mm 1.19
CIL
<3mm −2.68∗
from 3 to 4mm 2.05∗
≥5mm 1.31
PB 0 −1.61
11 . 6 2
Signiﬁcant diﬀerences: ∗P <. 05,Z= ±1.96.
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Figure 1: Percentages of sites with dichotomized Plaque Index
Scores (0-1) and (2-3) for the test (T) and control (C) groups.
Table 3: Spearman correlation among gingival growth (GO ≥ 2),
demographic and pharmacological variables for test and control
groups.
Variables Test Control
tv a l u e tv a l u e
Age −1.0383 0.6456
Gender 1.4074 1.4520
Dose 0.3986 —
Time of use 0.5574 —
Spearman Correlation.
Signiﬁcant diﬀerence: ∗P <. 05, t( t a b u l a t e d )= ±2.035.
understand the factors that act on this process. Today, more
than 20 drugs are known to induce GO [2].
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Figure 2: Percentages of sites with dichotomized Gingival Index
Scores (0-1) and (2-3) for the test (T) and control (C) groups.
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Figure 3: Percentages of sites with Probing Depth Values < 3mm,
from3to4mm,and ≥5mmforthetest(T)andcontrol(C)groups.
Few studies are currently available in the literature about
the inﬂuence of nifedipine in gingival manifestations. In the
present study, the mean age of patients in the test group was
69.5 years and the age variable did not show a correlation
with GO, in agreement with other studies [6, 9, 10, 17].
However, according to Thomason et al. [18]a n dJ a m e se ta l .
[19], younger patients show a higher prevalence of GO when
the association of nifedipine and cyclosporine treatment was
identiﬁed. Maybe this is an eﬀect of drug association and not
only related to the age of the patients.
In our group of patients, despite the larger number of
male patients in the test group than in the control group
(22:6), GO was more prevalent among females in both
groups (63.63% for the test group and 76.92% for the
control group). However, the Spearman test did not reveal
a correlation between patients gender and the occurrence4 ISRN Dentistry
0
10
20
30
40
50
60
70
80
90
100
(
%
) 47.81
77.3
40.81
18.99
11.76
CILV < 3mm CILV = 3mm
and 4mm
Clinical insertion level values = CILV
Test group
Control group
3.51
CILV ≥ 5mm
Figure 4: Percentages of sites with Clinical Insertion Level Values <
3mm, from 3 to 4mm, and ≥5mm for the test (T) and control (C)
groups.
Table 4: Spearman correlation between severity of gingival growth
(GO ≥ 2) and periodontal variables for groups.
Periodontal variables Test
tv a l u e
Control
tv a l u e
PI (2-3) 1.5366 2.6269∗
GI (2-3) 2.9879∗ 2.5203∗
PD
(<3mm) −5.4483∗ −2.9233∗
(from 3 to 4mm) 4.4462∗ 2.6914∗
(≥5mm) 5.4593∗ 2.1133∗
CIL
(<3mm) −2.2788∗ −1.9358
(from 3 to 4mm) 0.6250 1.9852
(≥5mm) 4.6975∗ 1.9970
PB 3.5932∗ 2.5119∗
Spearman Correlation.
Signiﬁcant diﬀerence: ∗P <. 05, t( t a b u l a t e d )= ±2.035.
of GO, in agreement with data reported by King et al. [9],
Margiotta et al. [20], and G¨ unc¨ u et al. [21]. According to
Seymour et al. [8], there are evidences that male patients
under treatment with nifedipine and cyclosporine are more
prone to a greater prevalence and severity of GO than female
patients [9, 20]. Since the medication may alter androgen
metabolism [22], reaching the gingival ﬁbroblasts, with a
consequentincreaseinthepropensity toGO[7,8].However,
the relation between GO and patient gender acting as a
hormonal cofactor has not been completely clariﬁed by this
study neither in the literature correlated [22].
In the present study, the dose and the time of nifedipine
u s ew e r ea l s on o tc o rr e l a t e dwi t hG O[ 6, 9, 10], in contrast to
the data reported by others authors [17, 18, 23]. Probably
the severity of GO has not been adequately correlated to
pharmacological variables because the events that determine
GO depend much more on local factors than on the
circulating plasma level of the drug. There are evidences that
the drug metabolites concentrated in gingival tissue interact
with inﬂammation chemical mediators, producing a stimuli
on ﬁbroblasts activity leading to an unbalance in the local
homeostasis, which eventually results in clinically observable
GO [24, 25]. Moreover, Seymour et al. [8] reported that the
most appropriate method for the assessment of the eﬀect of
pharmacological variables is blood analysis, which provides
a more precise understanding of the drug dose and GO
interaction.
Concerning the use of the Clinical Index DIGO [11]a s
a parameter for GO, we noted that the index was easily and
rapidly applicable. Considering that most of the indexes for
GO assessment are diﬃcult to reproduce, since they require
the preparation of casts, photographs, slide projection, and
several measurements, this index [11]h a sp r o v e dt ob e
advantageous. The present study seems to be the ﬁrst one to
use Clinical Index DIGO as a method for GO assessment.
The presence and intensity of PI is an important risk
factor for the development of GO in patients taking drugs
associated with gingival growth [8, 24] .T h eP Iw a sn o t
correlated with GO in the test group, whereas in the control
group, a correlation was observed.
In the control group, GO can be explained by the
presence of plaque, which may inﬂuence the development
of inﬂammatory gingival overgrowth. These results are in
agreement with the literature [5, 19, 23], which could be
explained by the fact that the PI for patients with GO were
artiﬁcially lower due to a possible improvement in oral
hygiene before the periodontal examination.
Gingival inﬂammation assessed by GI and PB was not
signiﬁcantly diﬀerent between the test and control groups.
However, the correlation test showed association of both GI
and PB with the degree of GO severity, and this association
was stronger for the test group. This result may explain the
inﬂuence of these periodontal variables on GO. Gingival
inﬂammation is considered an important risk factor in the
expression of GO correlated to nifedipine use [8]. The GI
observed in the present study showed results similar to those
reported by Barclay et al. [5], King et al. [9], G¨ unc¨ ue ta l .
[21], and Miranda et al. [23]. PB results were similar to those
reported byTavassolietal.[17],whereasMargiotta et al.[20]
did not detect a correlation between PB and GO.
The PD did not diﬀer signiﬁcantly between the test and
control groups, but GO was associated with an increase in
PD in both groups [5, 9, 18, 25]. King et al. [9] assessed CIL
in patients under treatment with nifedipine and concluded
that this was not a variable correlated with GO. In this study,
however,CILwascorrelatedwithGOinthetestgroupforthe
intervals of mild to severe loss of insertion, which indicates
that GO was due to the action of the medication and an
association of this eﬀect with periodontal inﬂammation. The
CIL was not correlated with GO for the control group. The Z
test showed signiﬁcant diﬀerences between the two groups
when the loss of insertion was moderate (CIL from 3 to
4mm). The GO was not deﬁned as signiﬁcant for the criteria
of periodontal variables, which in our study considered the
presence of GO to be signiﬁcant when the score was ≥2.
Due to the lack of studies evaluating CIL in patients under
treatment with drugs associated with GO, we observed thatISRN Dentistry 5
the assessment of this variable is more indicated in clinical
follow-up studies or long-term studies, in which it is possible
to evaluate the progress of periodontal disease.
5. Conclusion
GO diﬀered signiﬁcantly between the test and control
groups. Its prevalence in the control group may have been
due to an inﬂammatory reaction explained by the inﬂuence
ofperiodontalvariables(PI,GI,PD,andPB).Theprevalence
of GO in the test group can be explained by the eﬀect of
induction of nifedipine in gingival tissue. The proﬁle of the
study group consisted of older people with systemic diseases,
mainly cardiovascular diseases, with low socioeconomic
status and probably unmotivated with respect to their oral
health, which may cause ordinary periodontal inﬂammation
that can exacerbate the gingival overgrowth. The prevalence
of GO detected in this study is also related to the use of the
ClinicalIndexDIGO[11]asamethodforclinicalevaluation,
which may be interpreted as a diﬀerential factor compared to
previous studies.
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